StemRIM provided earnings guidance for the year ending July 31, 2023. For the period, The company expects operating revenue of ¥2,350 million, operating income of ¥146 million, net income of ¥170 million or ¥2.84 per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
470 JPY | 0.00% | +4.44% | -18.69% |
May. 09 | StemRIM to Seek Shareholders' Approval on Capital Stock Reduction | MT |
Mar. 13 | StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.69% | 187M | |
-0.28% | 90.59B | |
-0.92% | 38.99B | |
-9.57% | 34.09B | |
+64.51% | 26.38B | |
-17.98% | 15.02B | |
-6.74% | 13.17B | |
-9.76% | 11.88B | |
-47.31% | 10.65B | |
+7.19% | 9.25B |
- Stock Market
- Equities
- 4599 Stock
- News StemRIM
- StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023